News | November 04, 2013

Viztek, Matakina Partner to Integrate Breast Density Assessment

Hospitals, imaging centers to benefit from streamlined reporting, workflow to assist with meeting breast density legislation

viztek, opal-wRIS,

Viztek Opal-wRIS

November 4, 2013 – Viztek announced a new partnership with Matakina to integrate the company’s VolparaDensity software for analyzing digital mammography and tomosynthesis images and objectively assessing breast density with the Viztek Opal-PACS and Opal-wRIS for streamlined reporting and workflow. With 12 states having enacted legislation requiring patient notification and reporting of breast density, hospitals and imaging centers can now benefit from a streamlined workflow and integrated reporting to meet these mandates and streamline patient care.

“Our integration with VolparaDensity extends our capabilities and enables us to provide a more complete women’s healthcare software suite,” said Steve Deaton, vice president at Viztek. “With viewing, tracking, and now breast density software integration for RIS and PACS, Viztek has the first complete package for mammography and is enabling increased efficiency with the potential for better results.”

Cleared by the FDA, HealthCanada, the TGA and CE-marked in Europe, VolparaDensity is in use at sites across the globe helping radiologists assess breast density more objectively and enabling them to better consider who might benefit from additional screening.  Highly correlated to breast MR assessments, VolparaDensity generates an objective, automatic measurement of volumetric breast density and an FDA-cleared BI-RADS breast density category.

“Creating an objective, reproducible value within the RIS/PACS workflow is critical, not only for efficiency in practice, but for meeting the demands of new breast density legislation,” explains David Mezzoprete, vice president of sales at Matakina. “Our partnership with Viztek establishes a new model for diagnosis and exam follow-up in this new era of regulated density reporting, and we are proud to play a role in enhancing patient care.” 

Studies have shown traditional FFDM is only 48 percent effective in women with dense breasts, who also happen to be more susceptible to cancer. The estimated 40 percent of women in the United States who have dense breasts may benefit from adjunctive imaging modalities, such as ultrasound, MRI or molecular breast imaging, which can provide a clearer view of potential “hidden” cancers.

With the Viztek and Matakina partnership, smooth RIS/PACS integration of density data provides a significant increase in efficiency and also will aid in objectivity. The VolparaDensity output is done via the secondary capture to the Viztek Opal-PACS and structured report to the Opal-wRIS. The RIS will then take the data and put it automatically into the patient “lay letter” for mammography reporting functionality and streamlined workflow for the facility.

For more information:

Related Content

New ACR Data Science Institute Website Promotes Radiology Artificial Intelligence Development
News | Artificial Intelligence | October 20, 2017
The American College of Radiology Data Science Institute launched a new website to promote its efforts to advance,...
Study Examines Characteristics of Mobile Mammography Patients
News | Mammography | October 18, 2017
Significant differences were found among women receiving mammography at a cancer center versus those visiting a mobile...
Machine Learning Identifies Breast Lesions Likely to Become Cancer
News | Artificial Intelligence | October 18, 2017
A machine learning tool can help identify which high-risk breast lesions are likely to become cancerous, according to a...
Volpara Solutions to Showcase VolparaEnterprise Live! at RSNA
News | Mammography | October 16, 2017
Volpara Solutions will introduce VolparaEnterprise Live!, a mammography quality control tool, at the 2016 Radiological...
TMIST Mammography Study Opens Enrollment
News | Mammography | October 16, 2017
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST), the first randomized trial to compare two types of...
Sponsored Content | Whitepapers | Imaging | October 13, 2017
As we strive to increase value and decrease cost of health delivery, clinical collaboration and efficiency become key...
FDA Clears Siemens Magnetom Terra 7T MRI Device

FDA Clears Siemens Magnetom Terra 7T MRI Device

Technology | Magnetic Resonance Imaging (MRI) | October 12, 2017
The U.S. Food and Drug Administration (FDA) cleared the first 7 Tesla (7T) magnetic resonance imaging (MRI) device,...
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
ACR Appropriateness Criteria Add Topics, Increase Diagnostic Imaging Clinical Scenarios
News | Clinical Decision Support | October 11, 2017
October 11, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the...
News | Brachytherapy Systems | October 05, 2017
External researchers presented new clinical data supporting the use of iCAD’s Xoft Axxent Electronic Brachytherapy (eBx...
Overlay Init